Innovative Products
The Company will develop an innovative drug from the platform established in the production of the first two therapeutic candidates.
This drug will be target to a significant therapeutic area and will provide improvements in both methods of delivery as well as safety compared to existing marketed drugs.
The Hall laboratory has significant experience in developing targets to receptors and this strategy will form the basis of the research. The choice of target will be made in 2009.
